AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 282 min read$TXG

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

A jury ruled that Parse Biosciences, now part of Qiagen, willfully infringed three patents licensed to 10x Genomics. The patents were found valid, and 10x was awarded $4.8M in damages. 10x seeks further damages and an injunction. The case involved patents for single-cell analysis technology.

Original reporting
prnewswire.com
Published Aug 28, 2026, 7:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences — source image
Source · prnewswire.com
Decision brief

The 30-second read

$TXGBullishLow
01

Why it matters

The $4.8 M award validates 10x's IP strategy and may deter similar infringements.

02

Market read

Legal win for 10x Genomics could modestly lift its stock and underscores IP importance in the biotech tools market.

03

What to watch

Future injunction could restrict Parse's product sales, creating longer‑term revenue upside for 10x.

Relevance 6/10Novelty 7/10Timing: today

Background

10x Genomics licenses patents from Scale Biosciences, which were infringed by Parse Biosciences, now a Qiagen subsidiary.

Company-level read

Ticker impact

$TXGBullishMedium confidence
Context

Jury awarded 10x Genomics $4.8 million in damages for patent infringement by Parse Biosciences.

Expected impact

Modest upside as investors price in the award and potential injunction.

Evidence & confidence

The verdict is new and material, but the monetary amount is relatively small, limiting price move.

Market effects

Sector

Highlights IP risk for biotech and single‑cell analysis tool makers.

Regional

US biotech and life‑science equipment sector may see heightened diligence.

Global

Signals broader legal exposure for companies using similar patented technologies worldwide.

Counterpoint

What could challenge this read

Parse may appeal the verdict, potentially reducing the award and limiting upside for 10x.

Key entities

  • company
    10x Genomics

    US‑listed life‑science technology firm (TXG).

  • company
    Parse Biosciences

    Subsidiary of Qiagen (QGEN) found to infringe patents.

Read at source← All news

Related articles

SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min